
Opinion|Videos|November 22, 2023
Discussing Clinical Trial Enrollment for HER2-Positive Metastatic Breast Cancer With Your Oncologist
Author(s)Sara M. Tolaney, MD, MPH
Clinical trials should be considered at any point in a patient's journey with HER2-positive metastatic breast cancer, not just when standard options are exhausted, as they provide early access to promising therapies, novel combinations, and cutting-edge care.
Advertisement
Advertisement
Related Content
Advertisement
Advertisement
Trending on CURE
1
FDA Approves Zepzelca Plus Tecentriq for Extensive-Stage Small Cell Lung Cancer
2
All FDA Oncology Approvals From September 2025
3
Pelvic Physical Therapy After Cancer Restores Intimacy, Wellness
4
September Blood Cancer Updates: What Patients Should Know
5